Trial · NCT04405804
Early Administration of Ivabradine in Children With Heart Failure
NCT04405804, Phase 2, Unknown, Bambino Gesù Hospital and Research Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Early Administration of Ivabradine in Children With Heart Failure. Trials, record NCT04405804. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04405804
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Early Administration of Ivabradine in Children With Heart Failure
- NCT number
- NCT04405804
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 9 participants, estimated
- Lead sponsor
- Bambino Gesù Hospital and Research Institute
- Conditions
- Acute Heart Failure, Dilated Cardiomyopathy
- Interventions
- Ivabradine 5Mg Tab
- First posted
- 2020-05-28
- Last updated
- 2020-12-08
- Other registries' IDs
- eudract:2019-003902-29
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Heart rate in b.p.m. (mean (±SD) difference from baseline) at the end of maintenance | At the end of the two weeks maintenance period (17-29 days from enrollment) | To assess the response to ivabradine on heart rate after 14 days of stable therapy |
| Secondary | Heart rate in b.p.m. (mean (±SD) difference from baseline) at the end of follow-up | At the end of the 16 weeks follow-up period (129-141 days from enrollment) | To assess the response to ivabradine on heart rate after 16 weeks of follow-up |
| Secondary | Serum NT-proBNP in pg/mL (mean (±SD) difference from baseline) at the end of maintenance | At the end of the two weeks maintenance period (17-29 days from enrollment) | To assess the response to ivabradine on serum NT-proBNP levels after 14 days of stable therapy |
| Secondary | Serum NT-proBNP in pg/mL (mean (±SD) difference from baseline) at the end of follow-up | At the end of the 16 weeks follow-up period (129-141 days from enrollment) | To assess the response to ivabradine on serum NT-proBNP levels after 16 weeks of follow-up |
| Secondary | Correlation between heart rate and NT-proBNP value (Pearson correlation) at the end of maintenance | At the end of the two weeks maintenance period (17-29 days from enrollment) | To assess the correlation between heart rate and serum NT-proBNP levels after 14 days of stable therapy |
| Secondary | Correlation between heart rate and NT-proBNP value (Pearson correlation) at the end of follow-up | At the end of the 16 weeks follow-up period (129-141 days from enrollment) | To assess the correlation between heart rate and serum NT-proBNP levels after 16 weeks of follow-up |
| Secondary | Left ventricular function, calculated by 2D echocardiographic technique (calculation of left ventricular volume and ejection fraction - mean (±SD) difference from baseline) at the end of maintenance | At the end of the two weeks maintenance period (17-29 days from enrollment) | To assess EF, Left Ventricular End Diastolic Volume (LVEDV), Left Ventricular End Systolic Volume (LVESV) after 14 days of stable therapy |
| Secondary | Left ventricular function, calculated by 2D echocardiographic technique (calculation of left ventricular volume and ejection fraction - mean (±SD) difference from baseline) at the end of follow-up | At the end of the 16 weeks follow-up period (129-141 days from enrollment) | To assess EF, LVSV, LVDV after 16 weeks of follow-up |
| Secondary | Systolic blood pressure in mmHg (mean (±SD) difference from baseline) at the end of maintenance | At the end of the two weeks maintenance period (17-29 days from enrollment) | To assess the response to ivabradine on systolic blood pressure after 14 days of stable therapy |
| Secondary | Systolic blood pressure in mmHg (mean (±SD) difference from baseline) at the end of follow-up | At the end of the 16 weeks follow-up period (129-141 days from enrollment) | To assess the response to ivabradine on systolic blood pressure after 16 weeks of follow-up |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04405804
GET https://conductscience.org/api/trials/v1/NCT04405804/registered